916178-96-6

Upstream product

• 78495-63-3 (2-fluoro-6-methoxyphenyl)boronic acid 

Downstream Products

• 916065-16-2 5-Chloro-7-(2-fluoro-6-methoxyphenyl)-2-(4-methoxybenzyl)-2H-pyrazolo[4,3-d]pyrimidine 
• 916065-18-4 N-[2-Chloro-4-(trifluoromethyl)phenyl]-N-ethyl-7-(2-fluoro-6-methoxyphenyl)-2-(4-methoxybenzyl)-2H-pyrazolo[4,3-d]pyrimidine-5-amine 
• 916065-28-6 5-Chloro-7-(2-fluoro-6-methoxyphenyl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-d]pyrimidine 
• 916065-30-0 N-[2-Chloro-4-(trifluoromethyl)phenyl]-N-ethyl-7-(2-fluoro-6-methoxyphenyl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-d]pyrimidine-5-amine 
• 916065-17-3 N-[2-Chloro-4-(trifluoromethyl)phenyl]-7-(2-fluoro-6-methoxyphenyl)-2-(4-methoxybenzyl)-2H-pyrazolo[4,3-d]pyrimidine-5-amine 
• 916065-29-7 N-[2-Chloro-4-(trifluoromethyl)phenyl]-7-(2-fluoro-6-methoxyphenyl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-d]pyrimidine-5-amine 
• 916062-65-2 N-[2-chloro-4-(trifluoromethyl)phenyl]-N-ethyl-7-(2-methoxy-6-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidine-5-amine 

Relevant academic research and scientific papers

Fused pyridone compounds as kinase inhibitors

The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.

Four-ring-fused compound as well as preparation method and application thereof

The invention discloses a compound shown as a formula (I), an optical isomer and pharmacologically acceptable salts thereof, and application of the compound as a KRAS inhibitor.

PYRAZOLOPYRIMIDINE DERIVATIVE

A pyrazolopyrimidine derivative of the formula [I] wherein R1 is an optionally substituted aromatic ring group, an optionally substituted lower alkyl group or an optionally substituted amino group; R2 is an optionally substituted aromatic ring group; R3 is an optionally substituted lower alkyl group; and R4 is a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group or an amino group; or a pharmaceutically acceptable salt thereof is useful as an antagonist of CRF receptor.